List of Excipients in Branded Drug HALDOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	HALDOL	haloperidol	50458-255	LACTIC ACID
Janssen Pharmaceuticals Inc	HALDOL DECANOATE	haloperidol decanoate	50458-253	BENZYL ALCOHOL
Janssen Pharmaceuticals Inc	HALDOL DECANOATE	haloperidol decanoate	50458-253	SESAME OIL

Haldol Excipient Strategy and Commercial Opportunities: Formulations, Generics, Patents, and Market Entry

Last updated: August 28, 2026

Haldol, the branded haloperidol product, has limited patent protection but retains commercial value through formulation, supply, and administration advantages. The active ingredient is long genericized, so the strongest opportunities are in long-acting injectable delivery, preservative-free products, ready-to-use hospital presentations, oral liquid dosage forms, and excipient systems that improve tolerability, stability, or use in patients unable to swallow tablets.

The principal commercial constraint is price competition. A new Haldol-equivalent product would generally need either a lower-cost manufacturing platform, a differentiated presentation, a regulatory advantage, or a clinically relevant excipient improvement.

What products and dosage forms does Haldol include?

Haldol is the Janssen brand for haloperidol, a first-generation antipsychotic used in schizophrenia, acute agitation, delirium-related behavioral symptoms, and Tourette syndrome. Commercially relevant dosage forms include oral tablets, oral liquid formulations, immediate-release injection, and haloperidol decanoate long-acting injection.

Product category	Active ingredient	Typical route	Commercial role	Key excipient issue
Haldol tablets	Haloperidol	Oral	Chronic maintenance treatment	Tablet disintegration, swallowing, color, low-cost manufacture
Oral concentrate or solution	Haloperidol	Oral	Patients with swallowing or dose-flexibility needs	Taste masking, preservative system, dosing accuracy
Haldol injection	Haloperidol lactate	Intramuscular or intravenous, depending on product and labeling	Acute hospital use	Sterility, pH, preservative status, container compatibility
Haldol Decanoate	Haloperidol decanoate	Deep intramuscular injection	Long-acting maintenance treatment	Sesame-oil vehicle, injection volume, depot release, benzyl alcohol
Generic equivalents	Haloperidol or haloperidol decanoate	Oral or injectable	Price-driven substitution	ANDA sameness and supply reliability

Haldol Decanoate is the most defensible formulation platform because the decanoate ester and oil depot create a product that is materially different from immediate-release haloperidol. The opportunity is technically more demanding but commercially less exposed to simple tablet substitution.

What excipients are used in Haldol formulations?

The exact excipient profile depends on the manufacturer, dosage form, strength, and market. FDA labeling and product-specific prescribing information should control any formulation assessment.[1-4]

Haldol tablets

Haldol tablet formulations have historically used conventional solid-dose excipients, including lactose, starch, povidone, talc, and magnesium stearate. Colorants can vary by strength.

The formulation strategy is mature and inexpensive. A new oral tablet would face limited technical barriers unless it targets a specific need, such as:

• lactose-free or low-lactose administration;
• improved tablet dispersion;
• orally disintegrating delivery;
• reduced tablet size;
• pediatric or geriatric dosing;
• modified taste or swallowing characteristics;
• packaging that improves moisture protection.

A standard immediate-release tablet has little standalone protection from competition because generic manufacturers can generally replicate the dosage form with conventional excipients.

Oral liquid formulations

Haloperidol oral liquid products can use water, alcohol, glycerin, sweeteners, flavors, viscosity modifiers, and antimicrobial preservatives. The commercial priorities are dose uniformity, chemical stability, taste masking, and compatibility with oral syringes.

A liquid formulation can create a modestly differentiated product when it provides:

• preservative-free dosing;
• alcohol-free dosing;
• improved palatability;
• calibrated oral-syringe delivery;
• concentration options that reduce administration volume;
• stability after opening;
• suitability for feeding-tube administration.

Taste masking is commercially relevant because haloperidol has a bitter pharmaceutical taste. Ion-pairing, polymeric taste-masking systems, coated particles, cyclodextrins, and multiparticulate suspensions could support a differentiated 505(b)(2) strategy if the formulation provides measurable performance or adherence benefits.

Immediate-release injection

Haloperidol lactate injection is an aqueous parenteral formulation. The formulation must control pH, particulate matter, sterility, degradation, container interaction, and injection-site tolerability.

Potential excipient strategies include:

• preservative-free single-dose vials or ampoules;
• low-extractable and low-leachable container systems;
• prefilled syringes;
• ready-to-administer presentations;
• reduced dead-volume packaging;
• improved pH control;
• compatibility with emergency-department and ambulance workflows.

For hospital products, the commercial value of a new excipient system may come from reduced preparation time and medication-error risk rather than improved pharmacology.

Haldol Decanoate

Haldol Decanoate is an oil-based depot injection. The labeled formulation uses sesame oil and benzyl alcohol as inactive ingredients.[3] The oil vehicle controls the physical dispersion and release of haloperidol decanoate after intramuscular administration.

The principal formulation variables are:

• oil identity and purity;
• viscosity;
• drug concentration;
• benzyl alcohol content;
• particle size and suspension behavior;
• injection volume;
• syringeability;
• sedimentation and redispersibility;
• depot release profile;
• injection-site tolerability;
• container closure compatibility.

A substitute oil vehicle could create a clinically and regulatorily meaningful product only if it improves one or more of these characteristics. Potential vehicles include medium-chain triglycerides, refined vegetable oils, and other pharmaceutically accepted hydrophobic vehicles. A change from sesame oil would need careful assessment of allergy risk, oxidation, viscosity, depot kinetics, and bioequivalence.

What excipient opportunities are strongest for Haldol?

The strongest opportunities are concentrated in injectable and patient-use improvements rather than conventional tablets.

Opportunity	Technical rationale	Regulatory pathway	Commercial attractiveness
Preservative-free immediate-release injection	Removes benzyl alcohol or other preservative exposure	ANDA if sameness is established; 505(b)(2) if formulation differs materially	High for hospitals and vulnerable populations
Prefilled haloperidol injection	Reduces preparation steps and dosing errors	ANDA or 505(b)(2), depending on device and formulation	High in emergency and institutional settings
Alternative oil for decanoate	May reduce allergy concerns or improve injection performance	Likely 505(b)(2) or complex ANDA	High technical value, high development risk
Lower-volume decanoate injection	Improves patient experience and administration logistics	Complex ANDA or 505(b)(2)	Moderate to high
Long-acting microsphere or in situ depot	Could extend dosing interval or change release kinetics	505(b)(2) or new drug application	High, but requires substantial clinical evidence
Palatable oral liquid	Improves adherence and administration	ANDA or 505(b)(2)	Moderate
Orally disintegrating tablet	Addresses swallowing and administration	ANDA may be possible if bioequivalence and sameness are met	Moderate
Alcohol-free oral liquid	Expands pediatric, geriatric, and institutional use	ANDA or 505(b)(2)	Moderate
Tube-compatible liquid	Supports hospital and long-term-care use	ANDA or 505(b)(2)	Moderate
Stability-enhanced formulation	Extends shelf life or in-use stability	Regulatory value depends on demonstrated benefit	Moderate

The highest-value target is a ready-to-use, preservative-free injectable product. The second is an improved decanoate formulation with lower injection burden or better excipient tolerability.

What patents protect Haldol and haloperidol formulations?

The original composition-of-matter and early formulation protection for haloperidol has expired. Haloperidol was discovered and commercialized decades ago, and the drug is widely available from generic manufacturers.

For current commercial planning, the relevant distinction is between:

1. expired foundational patents;
2. potentially expired or weak formulation patents;
3. any later patents covering specific devices, depot systems, manufacturing processes, or combination products;
4. patents owned by third parties that could affect a redesigned product.

The established Haldol products do not present the type of active, high-value composition-of-matter estate associated with recently approved drugs. A standard haloperidol tablet or conventional injectable is therefore unlikely to obtain meaningful freedom-to-operate protection from the old Haldol brand alone.

Patent categories relevant to a new Haldol product

Patent category	Relevance to Haldol strategy	Expected strength
Haloperidol compound patents	Historical only	Expired
Standard tablet formulation patents	Limited unless narrowly claimed	Low
Oral liquid taste-masking patents	Could support differentiation	Moderate
Preservative-free injectable patents	Potentially useful if technically specific	Moderate
Oil-based decanoate formulation patents	Potentially valuable	Moderate to high
Prefilled syringe or autoinjector patents	Device-dependent	Moderate
Extended-release depot patents	Potentially strong if supported by clinical data	High
Manufacturing-process patents	Can create supply and cost advantages	Moderate
Packaging and container patents	Useful for commercial differentiation	Low to moderate

A current patent search should cover haloperidol, haloperidol decanoate, depot formulations, oil vehicles, benzyl alcohol alternatives, prefilled syringes, microspheres, in situ gels, and long-acting antipsychotic delivery systems. Patent risk is more likely to arise from third-party delivery technology than from the legacy Haldol brand.

What is the FDA Orange Book status of Haldol?

Haldol products were approved under legacy new drug applications, including Haldol and Haldol Decanoate products. The Orange Book identifies approved drug products, patent listings, and generic equivalents where applicable.[5]

The practical regulatory position is as follows:

• Haldol is an old small-molecule product.
• Generic haloperidol products are widely approved.
• Generic haloperidol decanoate products compete with the branded depot product.
• The active ingredient does not have biologic exclusivity or biosimilar protection.
• Any relevant listed patents must be checked by NDA number and dosage form because listings can differ among oral, immediate-release injectable, and decanoate products.
• A new product with a materially different excipient system may not qualify for a simple ANDA if the difference affects pharmaceutical equivalence, bioequivalence, safety, or labeling.

The Orange Book is central to an ANDA strategy, but it does not capture every patent that could affect freedom to operate. Device, manufacturing, formulation, and packaging patents may sit outside the listed-drug-patent framework.

When does Haldol lose exclusivity?

Haldol has already lost its primary market exclusivity. The original drug and most conventional dosage-form protection are long expired. Commercial exclusivity now depends on product-specific factors such as:

• FDA approval of a particular generic presentation;
• supply contracts;
• hospital formulary position;
• manufacturing reliability;
• injectable availability;
• device or packaging differentiation;
• patents covering a newly developed delivery system.

There is no biosimilar pathway for Haldol because haloperidol is a small molecule. Competitors enter through ANDAs, 505(b)(2) applications, or full new drug applications when the product has a materially different formulation, route, delivery system, or clinical profile.

Which companies are challenging or competing with Haldol?

Competition comes primarily from generic manufacturers rather than biosimilar developers. Companies that have marketed or sought approval for haloperidol products have included major generic suppliers and injectable specialists. Product availability varies by strength, route, and time period.

The competitive landscape includes:

• generic oral haloperidol tablet manufacturers;
• generic oral solution suppliers;
• generic haloperidol lactate injection manufacturers;
• generic haloperidol decanoate manufacturers;
• hospital-focused injectable companies;
• specialty pharmaceutical companies developing long-acting psychiatric products.

The relevant competitor set is not limited to products labeled Haldol. Risperidone long-acting injection, paliperidone palmitate, aripiprazole monohydrate, and aripiprazole lauroxil compete for maintenance-treatment budgets, although they do not compete as direct generic substitutes.[6-9]

How does Haldol compare with competing long-acting antipsychotics?

Product	Active ingredient	Administration	Formulation platform	Excipient opportunity
Haldol Decanoate	Haloperidol decanoate	Deep intramuscular injection	Oil depot	Lower volume, alternative vehicle, improved syringeability
Risperdal Consta	Risperidone	Intramuscular injection	Microsphere system	Complex reconstitution and device workflow
Perseris	Risperidone	Subcutaneous injection	In situ depot	Injection convenience and depot technology
Invega Sustenna	Paliperidone palmitate	Intramuscular injection	Aqueous nanosuspension	Particle engineering and injection volume
Abilify Maintena	Aripiprazole	Intramuscular injection	Aqueous suspension	Device, particle size, and administration
Aristada	Aripiprazole lauroxil	Intramuscular injection	Prodrug depot	Extended interval and administration support

Haldol Decanoate has a lower-cost active ingredient and a long history of clinical use. Its disadvantages include injection-site concerns, older pharmacology, extrapyramidal symptoms, and less favorable positioning against newer long-acting antipsychotics. An excipient-based product would need to improve administration, cost, supply, or tolerability without compromising the established depot profile.

What regulatory pathways apply to a new Haldol formulation?

ANDA pathway

An ANDA is the preferred route for a product that is pharmaceutically equivalent and bioequivalent to a reference listed drug. Conventional tablets and certain injections may fit this pathway if the formulation, strength, route, labeling, and performance meet FDA requirements.

An excipient change can complicate the ANDA if it alters:

• inactive-ingredient levels;
• route-specific safety;
• release characteristics;
• injection-site exposure;
• stability;
• bioequivalence;
• labeling.

505(b)(2) pathway

A 505(b)(2) application is more suitable for a product that relies partly on existing haloperidol data but differs in vehicle, dosage form, delivery system, concentration, route, or dosing schedule.

Examples include:

• a new oil vehicle for haloperidol decanoate;
• a long-acting depot with materially different release;
• an extended-release oral formulation;
• a prefilled injection with a distinct device and presentation;
• a preservative-free product that requires a new safety and stability package.

FDA drug-device combination considerations

A prefilled syringe, autoinjector, or integrated administration system introduces device requirements. The sponsor must address extractables and leachables, dose delivery accuracy, needle performance, container closure integrity, and human factors.

For hospital products, the device may create more commercial value than a modest excipient change because it can reduce preparation time and administration steps.

What manufacturing and intellectual-property barriers exist?

The main barriers are technical and operational rather than legacy composition-of-matter patents.

Decanoate manufacturing

Haloperidol decanoate products require control of ester quality, impurity profile, oil viscosity, suspension uniformity, sterilization strategy, and depot release. A new vehicle can create differences in:

• dissolution at the injection site;
• drug precipitation;
• local inflammation;
• systemic exposure;
• time to peak concentration;
• terminal elimination profile.

These variables make the depot product more difficult to copy than a standard tablet.

Sterile injectable manufacturing

A commercial injectable requires validated aseptic processing, sterile filtration where appropriate, container closure integrity, particulate control, and a reliable supply chain. Manufacturing capacity can be a competitive advantage when hospital buyers experience shortages.

Excipient supply

Sesame oil, benzyl alcohol, specialized oils, and parenteral-grade packaging materials can create supply risks. A product using multiple qualified suppliers may have an advantage over a formulation dependent on a single excipient or container source.

Intellectual property

A new formulation should be screened against patents covering:

• hydrophobic depot vehicles;
• biodegradable microspheres;
• in situ forming implants;
• particle-size reduction;
• injectable suspensions;
• prefilled syringes;
• low-volume injection systems;
• benzyl-alcohol-free parenteral products;
• long-acting antipsychotic dosing regimens.

A narrow patent claim limited to a particular excipient ratio, particle-size range, or manufacturing step may be enforceable but commercially vulnerable if design-around options are available.

What generic launch risks exist for Haldol?

Generic launch risk is high for standard oral products and moderate to high for conventional injectable products.

Product	Generic entry risk	Main reason
Immediate-release tablet	High	Mature dosage form and multiple generic suppliers
Oral liquid	Moderate to high	Formulation and taste differences create some complexity
Haloperidol lactate injection	Moderate	Sterile manufacturing and supply constraints
Haldol Decanoate	Moderate	Depot formulation and injectable manufacturing complexity
New long-acting depot	Low initially	Clinical, regulatory, manufacturing, and patent barriers
Prefilled injectable	Moderate	Device and human-factors requirements

Paragraph IV litigation is unlikely to create substantial commercial protection for legacy Haldol products unless a later-listed patent covers a specific formulation, device, or method of use. For a newly developed formulation, Paragraph IV risk would depend on the sponsor’s Orange Book listings and the scope of any asserted patents.

Settlement agreements involving Haldol would have to be evaluated against the relevant NDA, listed patents, ANDA filer, and launch terms. There is no basis to treat the old Haldol brand as having a current, broad patent-based barrier to generic entry.

What licensing opportunities exist for Haldol excipient technology?

Licensing opportunities are most credible in four areas:

1. Long-acting depot technology that improves dosing interval or injection burden.
2. Injectable vehicle technology that reduces local tolerability or allergy concerns.
3. Ready-to-use delivery systems for emergency and institutional care.
4. Oral taste-masking and pediatric liquid technology.

A licensee would generally prefer a platform with prior FDA use, scalable manufacturing, and a clear 505(b)(2) regulatory rationale. A novel excipient without parenteral precedent would increase development time and regulatory risk.

The strongest transaction structure would likely combine:

• an exclusive field license for haloperidol or long-acting antipsychotics;
• formulation know-how and analytical methods;
• access to qualified excipient suppliers;
• patent rights covering composition and manufacturing;
• clinical and regulatory support;
• milestone payments tied to IND, clinical, NDA, and launch events.

What revenue exposure does Haldol create?

Public revenue attribution for Haldol is limited because the brand competes with generics and product sales may be reported within broader Janssen or Johnson & Johnson portfolios. Brand revenue is therefore not a reliable proxy for the total haloperidol market.

Commercial exposure is concentrated in:

• hospital injectable purchasing;
• long-term-care and psychiatric-facility contracts;
• maintenance treatment with haloperidol decanoate;
• generic supply shortages;
• government and institutional tenders;
• pharmacy benefit substitution for oral products.

A differentiated injectable can command a better price than a standard tablet if it reduces preparation labor, administration time, wastage, or medication errors. The pricing case is weaker when the product changes only an inactive ingredient without improving workflow or clinical tolerability.

What is the best commercial strategy for a new Haldol product?

A practical product-development sequence is:

Near-term opportunity

Develop a preservative-free, ready-to-use haloperidol lactate injection in a prefilled syringe or low-dead-volume vial. The target buyers would be emergency departments, psychiatric hospitals, long-term-care facilities, and institutional pharmacies.

Mid-term opportunity

Develop a lower-volume or alternative-vehicle haloperidol decanoate injection. The program would require comparative pharmacokinetic, local-tolerability, stability, and injection-performance data.

Higher-risk opportunity

Develop an extended-duration depot that reduces administration frequency. This could create stronger patent protection but would require a substantial clinical and regulatory program.

Low-priority opportunity

Launch another conventional haloperidol tablet without a cost or supply advantage. The market is crowded, substitution is easy, and formulation patents would be difficult to make commercially durable.

Key Takeaways

• Haldol is a legacy small-molecule product with expired foundational exclusivity.
• Standard haloperidol tablets have limited differentiation and high generic-entry risk.
• Haldol Decanoate is the most attractive formulation platform because its oil depot is technically more complex.
• Sesame oil and benzyl alcohol are central excipient considerations for the decanoate product.
• Preservative-free injections, prefilled syringes, and lower-volume depot formulations offer the clearest commercial opportunities.
• A conventional copy is likely to follow an ANDA pathway; materially different delivery systems may require a 505(b)(2) application.
• Patent value is more likely to come from new depot, device, manufacturing, or excipient technology than from legacy Haldol patents.
• Biosimilar risk is irrelevant because haloperidol is a small molecule.
• The most defensible business case combines formulation differentiation with hospital workflow savings and reliable sterile supply.

FAQs

Can an excipient change create a new Haldol patent?

Yes. A patent may cover a specific excipient, concentration range, vehicle, particle-size distribution, release profile, manufacturing process, or device configuration. The patent must provide technical differentiation and withstand design-around and validity challenges.

Is Haldol Decanoate harder to develop than oral haloperidol?

Yes. The depot vehicle affects release kinetics, injection-site exposure, systemic pharmacokinetics, and dose equivalence. Sterile injectable manufacturing also creates additional development and supply requirements.

Could benzyl alcohol be removed from Haldol Decanoate?

Potentially, but removal would require a reformulated product with appropriate antimicrobial control, container strategy, sterility assurance, stability data, and regulatory support. The effect on depot performance would need to be demonstrated.

Would a prefilled Haldol injection qualify for an ANDA?

Possibly. If the drug formulation is pharmaceutically equivalent and bioequivalent to the reference product and the device does not create a material difference, an ANDA may be available. A materially different formulation or delivery system could require a 505(b)(2) application.

Which Haldol formulation has the best licensing potential?

A long-acting decanoate formulation with lower injection volume, improved tolerability, or an extended dosing interval has the highest licensing potential. The opportunity is larger when the technology applies to other long-acting antipsychotics.

References

1. U.S. Food and Drug Administration. (n.d.). Haldol: Haloperidol tablet prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Haloperidol lactate injection prescribing information. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Haldol Decanoate: Haloperidol decanoate injection prescribing information. DailyMed.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
6. U.S. Food and Drug Administration. (n.d.). Risperdal Consta prescribing information.
7. U.S. Food and Drug Administration. (n.d.). Invega Sustenna prescribing information.
8. U.S. Food and Drug Administration. (n.d.). Abilify Maintena prescribing information.
9. U.S. Food and Drug Administration. (n.d.). Aristada prescribing information.